|Specificity:||The antibody MEM-43 reacts with well defined epitope (W40, R-53) on CD59 (Protectin), an 18-20 kDa glycosylphosphatidylinositol (GPI)-anchored glycoprotein expressed on all hematopoietic cells; it is widely present on cells in all tissues.
HLDA IV; WS Code NL 705
HLDA V; WS Code AS S013
HLDA V; WS Code BP BP345
HLDA V; WS Code T T-103
|Immunogen:||Thymocytes and T lymphocytes|
|Preparation:||The purified antibody is conjugated with Pacific Blue™ under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.|
|Storage Buffer:||The reagent is provided in phosphate buffered saline (PBS) containing 15 mM sodium azide and 0.2% (w/v) high-grade protease free Bovine Serum Albumin (BSA) as a stabilizing agent.|
|Storage / Stability:||Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light.
Do not use after expiration date stamped on vial label.
Short-term exposure to room temperature should not affect the quality of the reagent. However, if reagent is stored under any conditions other than those specified, the conditions must be verified by the user.
|Usage:||The reagent is designed for Flow Cytometry analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension.
The content of a vial (0.4 ml) is sufficient for 100 tests.
|Expiration:||See vial label|
|Lot Number:||See vial label|
|Background:||CD59 (Protectin) is a small (18-20 kDa) GPI-anchored ubiquitously expressed inhibitor of the membrane attack complex (MAC). It is thus the key regulator that preserves the autologous cells from terminal effector mechanism of the complement cascade. CD59 associates with C5b-8 complex and thereby counteracts appropriate formation of cytolytic pore within the plasma membrane. CD59 is also an low-affinity ligand of human CD2 and causes T cell costimulation.|
*Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ: Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 1990 Sep;71(1):1-9.
*Rooney IA, Davies A, Griffiths D, Williams JD, Davies M, Meri S, Lachmann PJ, Morgan BP: The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells. Clin Exp Immunol. 1991 Feb;83(2):251-6.
*Menu E, Tsai BC, Bothwell AL, Sims PJ, Bierer BE: CD59 costimulation of T cell activation. CD58 dependence and requirement for glycosylation. J Immunol. 1994 Sep 15;153(6):2444-56.
*Baalasubramanian S, Harris CL, Donev RM, Mizuno M, Omidvar N, Song WC, Morgan BP: CD59a is the primary regulator of membrane attack complex assembly in the mouse. J Immunol. 2004 Sep 15;173(6):3684-92.
*Horejsi V, Hilgert I, Kristofova H, Bazil V, Bukovsky A, Kulhankova J: Monoclonal antibodies against human leucocyte antigens. I. Antibodies against beta-2-microglobulin, immunoglobulin kappa light chains, HLA-DR-like antigens, T8 antigen, T1 antigen, a monocyte antigen, and a pan-leucocyte antigen. Folia Biol (Praha). 1986;32(1):12-25. (original description of MEM-43 antigen)
IMPORTANT ARTICLE *Robert Sutherland D, Keeney M, Illingworth A: Practical guidelines for the high-sensitivity detection and monitoring of paroxysmal nocturnal hemoglobinuria (PNH) clones by flow cytometry. Cytometry B Clin Cytom. 2012 Apr 12. doi: 10.1002/cyto.b.21023. [Epub ahead of print] Note: This article recommends PE-conjugated MEM-43 as a good reagent for red blood cell analysis of PNH (Paroxysmal Nocturnal Hemoglobinuria) by flow cytometry.
*Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989).
*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
*Forsberg UH, Bazil V, Stefanova I, Schroder J: Gene for human CD59 (likely Ly-6 homologue) is located on the short arm of chromosome 11. Immunogenetics. 1989;30(3):188-93.
*Stefanova I, Hilgert I, Kristofova H, Brown R, Low MG, Horejsi V: Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. Mol Immunol. 1989 Feb;26(2):153-61.
*Stefanova I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H: GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science. 1991 Nov 15;254(5034):1016-9.
*Cinek T, Horejsi V: The nature of large noncovalent complexes containing glycosyl-phosphatidylinositol-anchored membrane glycoproteins and protein tyrosine kinases. J Immunol. 1992 Oct 1;149(7):2262-70.
*Bodian DL, Davis SJ, Morgan BP, Rushmere NK: Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J Exp Med. 1997 Feb 3;185(3):507-16.
Cebecauer M, Cerny J, Horejsi V: Incorporation of leucocyte GPI-anchored proteins and protein tyrosine kinases into lipid-rich membrane domains of COS-7 cells. Biochem Biophys Res Commun. 1998 Feb 24;243(3):706-10.
*Ilangumaran S, Briol A, Hoessli DC: CD44 selectively associates with active Src family protein tyrosine kinases Lck and Fyn in glycosphingolipid-rich plasma membrane domains of human peripheral blood lymphocytes. Blood. 1998 May 15;91(10):3901-8.
*Omidvar N, Wang EC, Brennan P, Longhi MP, Smith RA, Morgan BP: Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. J Immunol. 2006 Mar 1;176(5):2915-23.
*And many other.
This product is provided under an agreement between Molecular Probes, Inc. (a wholly owned subsidiary of Invitrogen Corporation), and Exbio Praha, a.s., and the manufacture, use, sale or import of this product may be subject to one or more U.S. patents, pending applications, and corresponding non-U.S. equivalents, owned by Molecular Probes, Inc. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity), including use in flow cytometry that does not utilize a bead based array, but excluding use in combination with microarrays or High Content Screening. The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Molecular Probes, Inc., Business Development, 29851 Willow Creek Road, Eugene, OR 97402, USA, Tel: (541) 465-8300. Fax: (541) 335-0504.
For laboratory research only, not for drug, diagnostic or other use.
EXBIO Praha | Nad Safinou II 341 | 252 42 Vestec u Prahy | Czech Republic